Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Sterility

LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure

Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is the reason pyrogen testing exists as a separate discipline.

The unit of account is the endotoxin unit, defined against an international reference standard rather than a mass, because different lipopolysaccharide preparations differ substantially in potency. One endotoxin unit corresponds to roughly a tenth of a nanogram of the reference material. The limit for a parenteral product other than an intrathecal one is conventionally derived from a threshold pyrogenic dose of five endotoxin units per kilogram of body weight per hour, divided by the maximum dose administered in that period. The arithmetic takes one line, and the Journal has yet to see it printed on a research-peptide certificate.

What endotoxin is, and why sterility does not address it

Endotoxin is a structural component of the outer membrane of Gram-negative bacteria: a lipopolysaccharide with a lipid A anchor that is the pyrogenic moiety, a core oligosaccharide, and a variable O-antigen chain. It is shed during growth and released in quantity on cell lysis, which means that killing a bacterial population does not remove its endotoxin and may increase the free concentration.

Three physical properties make it a separate discipline. It is thermally robust, surviving autoclave conditions with little loss of pyrogenicity, so terminal sterilisation is not a depyrogenation step. It is small and amphipathic, forming aggregates that pass a 0.22 micron membrane without difficulty, so sterilising filtration is not a depyrogenation step either. And it is active in humans at very low mass — the threshold pyrogenic dose corresponds to something in the region of a nanogram per kilogram of body weight.

The practical consequence is stark. A vial can pass a sterility test, contain no viable organism of any kind, and carry an endotoxin burden many times a defensible parenteral limit, because the organisms responsible died somewhere upstream in a water system, a holding tank or a poorly stored component.1

Three method families, and what each returns

The gel-clot method is the oldest and simplest: lysate is combined with the sample, incubated, and the tube inverted. A firm clot that does not slip is a positive. It is a limit test, and by testing serial dilutions it becomes semi-quantitative. Its virtues are robustness and independence from instrumentation; its limitation is resolution.

Turbidimetric methods read the increasing turbidity produced by clotting protein formation, either as an endpoint at fixed time or kinetically as the time to reach a defined turbidity. Chromogenic methods substitute a synthetic peptide substrate that releases a chromophore when cleaved by the activated enzyme, and read absorbance. The kinetic chromogenic variant — measuring the time to a defined absorbance change against a standard curve — is the method of record for most modern release testing, offering quantitation across several orders of magnitude from a small sample volume.

All three are compendial, all three require a demonstration that the sample matrix neither inhibits nor enhances the reaction, and all three are calibrated against an international reference endotoxin rather than against a mass. A result reported without the method and without the inhibition-enhancement result is, once again, a number without a procedure.2

A stated negative is a fact a reader can use. An omission is a space a reader fills with an assumption.

The standing rule in this department

The endotoxin limit, calculated

The limit is derived, not looked up. For a parenteral product other than an intrathecal one, the threshold pyrogenic dose is taken as five endotoxin units per kilogram of body weight per hour. The endotoxin limit for the product is that figure divided by the maximum dose per kilogram administered within an hour. For an intrathecal route the threshold falls to 0.2 endotoxin units per kilogram, a twenty-five-fold reduction that reflects the absence of the systemic buffering the bloodstream provides.

Work it for a concrete case. A seventy-kilogram subject has an hourly allowance of three hundred and fifty endotoxin units. A vial nominally containing five milligrams of peptide, reconstituted to two millilitres, from which a fifth of a millilitre is drawn, delivers a tenth of the vial contents. If the whole vial carried three hundred and fifty endotoxin units, that draw would deliver thirty-five — a tenth of the allowance. The limit expressed per milligram of peptide is what a certificate should carry, because it is the only form of the number that survives a change in reconstitution volume.

None of the arithmetic is difficult. What is missing from this trade is not the calculation but the measured numerator.3

Five determinations: method, sample fate and what a private buyer pays
DeterminationMethod familySampleTurnaroundRelative cost
PurityReversed-phase HPLC, UVA few mg, non-destructive to batch2–7 days
IdentityLC–MS, optionally MS/MSA few mg3–10 days1–2×
Peptide contentElemental N or quantitative AAASeveral mg2–4 weeks2.5–3×
Bacterial endotoxinKinetic chromogenic LAL or rFC<1 mL reconstituted3–10 days2–3×
SterilityMembrane filtration, 14-day incubationEntire container, destroyed3–4 weeks6–10×
Relative cost is expressed against a single generic-gradient purity run as 1×, from quotations obtained by the Journal from contract laboratories during the year. Sterility pricing assumes a single container rather than a compendial sample of twenty.

Low endotoxin recovery, and the clean result that is wrong

The most uncomfortable finding in endotoxin testing over the past fifteen years is that certain formulation matrices cause added endotoxin to become undetectable over time. Spike a known quantity of reference endotoxin into a solution containing a non-ionic surfactant and a chelating buffer, hold it, and the recoverable endotoxin declines — sometimes to a small fraction of what was added — while nothing has been removed. The lipopolysaccharide aggregate state has changed, and the assay cannot see what it cannot bind.

The phenomenon is called low endotoxin recovery, and it matters because the combination of polysorbate with citrate or phosphate is extremely common in peptide and protein formulations. A hold-time study — spiking the actual product matrix and measuring recovery across the intended sample storage interval — is the standard mitigation, and it is now expected as part of method suitability for products in that formulation space.

The implication for a reader is narrow but worth stating. A negative endotoxin result on a surfactant-containing formulation, reported without a hold-time recovery study, is weaker evidence than it appears. A negative result on a reconstituted lyophilised peptide in plain water for injection, tested promptly, is considerably stronger.4

Depyrogenation, and the step that gets skipped

Because endotoxin survives sterilisation, glass components require a separate treatment. The standard is dry heat: a tunnel or oven cycle at two hundred and fifty degrees or above, validated to achieve at least a three-log reduction in a deliberately applied endotoxin challenge. Vials emerging from a qualified depyrogenation tunnel are both sterile and pyrogen-free, and they remain so only if the subsequent handling maintains it.

Elastomeric closures cannot take that treatment and are instead washed, siliconised and steam-sterilised by a validated cycle, with endotoxin control achieved by the washing step and specified as a limit per stopper. Water for injection is controlled at source, with a compendial endotoxin specification, and a water system is the commonest origin of a pyrogen problem in an otherwise competent facility.

Depyrogenation is also, in the Journal’s experience of asking, the step most frequently absent from descriptions of small fill operations. Autoclaved vials are sterile. Autoclaved vials are not depyrogenated, and an operation that describes its glass preparation solely in terms of autoclaving has told you something specific about what it has not done. We put this point to eleven correspondents; two said their glass is depyrogenated by dry heat with a validated cycle, and one asked us what depyrogenation was, which we took as a straight answer and a useful one.

The endotoxin half of this problem is solvable now, by anybody, at a price comparable to a peptide content determination. That is the single most practically useful sentence in this article. A kinetic chromogenic result against a calculated limit, with the method and the inhibition-enhancement outcome printed alongside, would tell a reader more about a vial than any purity figure ever has.

References

  1. “Endotoxin detection and control in parenteral manufacture: a review of methods and limits.” Journal of Pharmaceutical Sciences. 2020;109(1):18–31.
  2. United States Pharmacopeia. General Chapter ⟨85⟩ Bacterial Endotoxins Test. USP–NF, Rockville, MD.
  3. European Pharmacopoeia. Chapter 5.1.10 — Guidelines for Using the Test for Bacterial Endotoxins. Council of Europe, Strasbourg.
  4. “Low endotoxin recovery in biopharmaceutical formulations: mechanisms and hold-time study design.” PDA Journal of Pharmaceutical Science and Technology. 2017;71(6):452–467.

Letters to the Editor

3 printed

Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.

I have worked in aseptic fill for nineteen years and your section on media fills understates one thing. The scale is not the hard part. Running the simulation with every intervention the real process contains — every stopper jam, every environmental sample, every gowning break — is the hard part, and a simulation that omits the interventions is theatre with a growth medium in it.

M. Karlsen, Kristiansand

The Journal replies

That is a better statement of the point than ours and we have amended the section to make the interventions explicit. The scale figure without the intervention requirement is exactly the sort of number that gets quoted as reassurance.

Your table of responses records four declines citing research-use-only status, and you call that a legally sound answer. It is also the answer that ends the conversation. What would you have a supplier say instead?

N. Fairweather, Hamilton

The Journal replies

Something like: this product is sold for research use, is not represented as a sterile injectable, and here is what we nonetheless do — aseptic fill in a classified environment, bioburden to a stated specification, post-use filter integrity testing. Three of our correspondents said close to that. It concedes nothing legally and tells a reader a great deal.

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.

G. Papadakis, Thessaloniki

The Journal replies

Because we could not afford twenty, and because the two results are reported as what they are: two vials, each destroyed, telling us nothing about their batches. The purpose was to establish that the test is commercially available to a private purchaser and what it costs, not to characterise anything. We should have said that in the article rather than in this reply.

Related coverage